Prime Medicine, Inc. (PRME)
$3.99+11.45%Close
BUYRECOVERY · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $721M
- Beta
- 2.35
- P/E (TTM)
- -3.18
- Short % float
- 54.28%
- Days to cover
- 8.4
- SI change
- -0.1%
- 1W
- +33.89%
- 1M
- +19.10%
- vs SPY 1W
- +32.73%
- vs SPY 1M
- +16.11%
Industry peers
FMP comparable companies · ranked by market cap
- MRVIBUYMaravai LifeSciences Holdings, Inc.$2.2BCRISISQ -1$7.90+3.19%
- VIRBUYVir Biotechnology, Inc.$1.9BBULLQ 13$11.17+5.22%
- SEPNSELLSepterna Inc$1.7BRECOVERYQ 28$37.71+3.98%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 5$20.43-0.15%
- BCAXSELLBicara Therapeutics Inc. Common Stock$1.2BCRISISQ -9$17.63+1.39%
- REPLSELLReplimune Group, Inc.$1.1BRECOVERYQ 14$13.07+2.91%
- KURASELLKura Oncology, Inc.$945MBEARQ 12$10.65+0.76%
- PROKSELLProKidney Corp.$578MRECOVERYQ 1$1.72+4.82%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on PRME?
- LOPJLB’s latest quantitative signal on Prime Medicine, Inc. (PRME) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is PRME in?
- Prime Medicine, Inc. (PRME) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Prime Medicine, Inc. (PRME) do?
- Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor proteinâa hybrid composed of a Cas protein and a reverse transcriptase enzymeâwith a specialized pegRNA molecule. This pe…